<DOC>
	<DOCNO>NCT01447446</DOCNO>
	<brief_summary>This prospective , multicenter , observational cohort study evaluate efficacy safety pegylated interferon alfa ( peginterferon alfa ) ( e.g . Pegasys ) plus ribavirin treatment regimen contain direct-acting antiviral participant chronic hepatitis C treatment-na√Øve treatment-experienced HIV HCV co-infected . Data collect participant receive treatment accord current Summary Product Characteristics ( SPC ) local label duration treatment 24-week follow-up .</brief_summary>
	<brief_title>An Observational Study Dual And Triple Therapies Based Peginterferon Alfa ( e.g . Pegasys ) Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Adult ( accord local legislation ) participants Chronic hepatitis C ( HCV ) Naive treatment experience , HIVHCV coinfected HCV monoinfected Receiving treatment HCV pegylated interferon plus ribavirin regimen contain directacting antiviral ( DAA ) accord standard care line current SPC/local labeling Contraindications accord SPC/local labeling Treatment start &gt; 4 week enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>